SY-1530

N/A

Report date: 2024/11/24 20:00:04
NME

Base Information

Drug NameSY-1530
Drug Alias NameCT-1530SY-1530
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesBeijing Centaurus Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Centaurus Biopharma Co Ltd
Active IndicationsN/A
Inactive IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[6] 

Other Information

ATC CodeN/A
Related LinksN/A